Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Pituitary tumors

Cabergoline versus bromocriptine: a meta-analysis?

Nature Reviews Endocrinology volume 7, pages 254–255 (2011)Cite this article

A systematic review and meta-analysis by Dos Santos Nunes et al. has compared the benefits and risks of cabergoline versus bromocriptine for the treatment of patients with hyperprolactinemia. This analysis confirms previous reports that cabergoline is more efficacious and better tolerated than bromocriptine.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dos Santos Nunes, V., El Dib, R., Boguszewski, C. L. & Nogueira, C. R. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary doi:10.1007/s11102-010-0290-z.

  2. Gillam, M. P., Molitch, M. E., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485–534 (2006).

    Article  CAS  Google Scholar 

  3. Colao, A. et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab. 82, 876–883 (1997).

    Article  CAS  Google Scholar 

  4. Iyer, P. & Molitch, M. E. Positive prolactin response to bromocriptine in two patients with cabergoline resistant prolactinomas. Endocr. Pract. doi:10.4158/EP10369.CR

  5. Ono, M. et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J. Clin. Endocrinol. Metab. 93, 4721–4727 (2008).

    Article  CAS  Google Scholar 

  6. Molitch, M. E. The cabergoline-resistant prolactinoma patient: new challenges. J. Clin. Endocrinol. Metab. 93, 4643–4645 (2008).

    Article  CAS  Google Scholar 

  7. Dekkers, O. M. et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 95, 43–51 (2010).

    Article  CAS  Google Scholar 

  8. Molitch, M. E. Prolactinomas and pregnancy. Clin. Endocrinol. (Oxf.) 73, 147–148 (2010).

    Google Scholar 

  9. Smith, G. C. & Pell, J. P. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomized controlled trials. BMJ 327, 1459–1461 (2003).

    Article  Google Scholar 

  10. Lewiecki, E. M. & Binkley, N. Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis. Endocr. Pract. 15, 573–579 (2009).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 North Michigan Avenue, Chicago, 60611, IL, USA

    Mark E. Molitch

Authors
  1. Mark E. Molitch
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molitch, M. Cabergoline versus bromocriptine: a meta-analysis?. Nat Rev Endocrinol 7, 254–255 (2011). https://doi.org/10.1038/nrendo.2011.33

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2011.33

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing